Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 5/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19954609 | 0.93 | TRPV1 (0.42) | ARTRPV1GRIA2TRPV4CCR2 | |
| SCHEMBL18164095 | 0.85 | AR (0.43) | ARTRPV1TRPV4CCR2KCNH2 | |
| SCHEMBL19954587 | 0.83 | AR (0.41) | ARTRPV1GRIA2TRPV4CCR2 | |
| SCHEMBL18164068 | 0.77 | AR (0.39) | ARTRPV1GRIA2TRPV4CCR2 | |
| SCHEMBL19954538 | 0.77 | AR (0.40) | ARTRPV1GRIA2TRPV4CCR2 | |
| SCHEMBL21024103 | 0.75 | TRPV1 (0.42) | TRPV1KCNH2LRRK2 | |
| SCHEMBL21023833 | 0.75 | TRPV1 (0.40) | TRPV1GRIA2KCNH2LRRK2 | |
| SCHEMBL19954551 | 0.72 | TRPV1 (0.35) | TRPV1GRIA2LRRK2 | |
| SCHEMBL19954622 | 0.71 | GAA (0.37) | TRPV1KCNH2LRRK2 | |
| SCHEMBL19954668 | 0.68 | PLAT (0.36) | ARTRPV1GRIA2LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9914706-B2 | N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2018-03-13 | — | — | US | disclosed |